From target discovery to large-scale manufacturing, the biopharmaceutical workflow is a carefully orchestrated process that blends biology, engineering, and analytics. As therapies become more complex and personalized, the need for robust, scalable, and well-integrated solutions has never been greater.
Understanding the full value chain and choosing the right technologies at each stage is key to accelerating development, ensuring quality, and ultimately delivering life-changing therapies to patients.
In this article, we provide a practical overview of the end-to-end biopharmaceutical workflow, highlighting the critical technologies of our partners that support each phase, from discovery to analytics and quality control.
-
Target Discovery & Validation: Where It All Begins
The biopharmaceutical journey starts with identifying a biological target: a protein, receptor, gene, or pathway implicated in disease. Advances in genomics, proteomics, and high-throughput screening have dramatically accelerated this stage.
Modern discovery relies heavily on high-throughput and high-sensitivity analytical tools. Screening platforms, detection technologies, and next-generation sequencing (NGS) systems enable researchers to evaluate thousands of candidates efficiently while generating high-quality, reproducible data.
Revvity plays a central role at this stage, offering advanced NGS, screening, and analytical platforms that support target identification, assay development, and early validation. Complementing this, Berthold Technologies and Hidex provide sensitive detection systems, such as luminometers, radiometric and fluorescence-based instruments, that are widely used in functional assays and molecular screening.
-
Cell Line Development: Building the Production Engine
Once a promising target and therapeutic modality are selected, attention turns to cell line development. This stage focuses on engineering a stable, high-producing cell line capable of expressing the desired biologic with consistent quality.
Cell line development is a data-intensive process, requiring robust analytics to assess expression levels, genetic stability, and product integrity. Automation, advanced imaging, and molecular characterization tools are increasingly important to shorten development timelines.
Revvity’s analytical and genomic solutions support clone selection and characterization, while detection systems from Berthold Technologies and Hidex enable precise quantification of reporter activity, metabolic markers, and functional readouts during screening.
-
Upstream Processing: Scaling Biology
Upstream processing focuses on cultivating cells at scale to produce the target biologic. This is where laboratory-scale success must translate into reproducible, scalable manufacturing processes. In this step, consistency is key, as even small variations in upstream conditions can affect product quality downstream.
For this stage, we have partnered with Cytiva, one of our major technology partners, offering single-use and stainless-steel bioreactors, cell culture media and supplements, and fluid management and filtration solutions. Together, these technologies enable scalable, flexible, and well-controlled upstream workflows suitable for both clinical and commercial manufacturing.
-
Downstream Purification: Turning Harvest into Product
Downstream processing is often the most complex and cost-intensive part of biomanufacturing. Its goal is to isolate and purify the target molecule while removing host cell proteins, DNA, aggregates, and other impurities. This stage demands robust, scalable purification strategies that maintain product integrity while meeting strict regulatory standards.
Cytiva’s downstream portfolio, including chromatography resins, ÄKTA™ systems, filtration, and single-use technologies, supports efficient purification across a wide range of biologics. Advanced process development tools help teams optimize yield, consistency, and cost of goods early in development, reducing risk at scale.
-
Analytics & Quality Control: Ensuring Safety and Consistency
Analytics and quality control are not confined to a single stage. Instead, they are embedded throughout the entire biopharmaceutical workflow. From early discovery to final product release, data integrity and analytical rigor are essential. Highly sensitive detection systems are critical, especially when measuring low-abundance signals or working with radiolabeled or luminescent assays.
Berthold Technologies and Hidex are widely recognized for their luminometers, radiometric detectors, and multimode readers, supporting applications ranging from assay development to quality control testing. Combined with Revvity’s advanced analytical and genomic platforms, laboratories gain a comprehensive toolkit for confident decision-making across development and manufacturing.
Connecting the Dots Across the Value Chain
What makes modern biopharmaceutical development successful is not just innovation at individual stages but integration across the entire workflow. Data generated in discovery informs cell line design. Upstream decisions affect downstream performance. Analytics ensure control, compliance, and continuous improvement at every step.
By leveraging complementary technologies from our trusted suppliers, such as Cytiva for bioprocessing and purification, Revvity for discovery and analytical insights, and Berthold Technologies and Hidex for high-sensitivity detection, biopharma teams can build workflows that are not only efficient but also future-proof.
Discover our complete portfolio of solutions for biotechnology and biopharmaceutical applications here.